



Beta amyloid MoAs include: Passive immunotherapies (Monoclonal antibodies, Intravenous immunoglobulins), Active immunotherapies, Aggregation inhibitors, Neuronal restorers, Gamma secretase inhibitors, and Beta secretase inhibitors.

Mechanism of Action	US Reg. / Phase III (N=5)	Phase II (N=24)	Phase I (N=40)
Monoclonal Antibodies (N=8)	<ul style="list-style-type: none"> <li>Bapineuzumab (PFE/JNJ/ELN)</li> <li>Solanezumab (LLY)</li> </ul>	<ul style="list-style-type: none"> <li>Ponezumab (PFE)</li> <li>Gantenerumab (Roche/Chugai/MorphoSys)</li> <li>Crenzeumab (Roche/ AC Immune)</li> </ul>	<ul style="list-style-type: none"> <li>933776 (GSK)</li> <li>PF-05236812 (PFE, JNJ, ELN)</li> <li>BAN2401 (Eisai/BioArtic)</li> </ul>
Intravenous Immunoglobulins (N=3)	<ul style="list-style-type: none"> <li>Gammagard (BAX)</li> </ul>	<ul style="list-style-type: none"> <li>Octagam (Octapharm)</li> <li>NewGam (Sutter Health)</li> </ul>	
Active Immunotherapies (N=6)		<ul style="list-style-type: none"> <li>Vanutide Cridificar (PFE/JNJ/ELN)</li> <li>CAD106 (NVS/Cytos)</li> <li>AD02 (GSK/AFFiRiS)</li> </ul>	<ul style="list-style-type: none"> <li>V950 (MRK)</li> <li>ACI-24 (AC Immune)</li> <li>AD03 (AFFiRis)</li> </ul>
Aggregation Inhibitors (N=3)	<ul style="list-style-type: none"> <li>Scyllo-inositol (ELN)</li> </ul>		<ul style="list-style-type: none"> <li>NP-61 (Noscira)</li> <li>Exebryl-1 (Proteotech)</li> </ul>
Neuronal Restorers (N=1)		<ul style="list-style-type: none"> <li>PBT-2 (Prana)</li> </ul>	
Gamma Secretase Inhibitors (N=8)		<ul style="list-style-type: none"> <li>Avagacestat (BMS)</li> <li>BMS708163 (BMS)</li> </ul>	<ul style="list-style-type: none"> <li>Begacestat (PFE)</li> <li>MK-0752 (MRK)</li> <li>ELND-006 (ELN)</li> <li>E2212 (Eisai)</li> <li>NGP 555 (NeuroGenetic)</li> <li>GSM EVP-0962 (EnVivo)</li> </ul>
Beta Secretase Inhibitors (N=7)			<ul style="list-style-type: none"> <li>AZD3839 (AZN)</li> <li>MK-8931 (MRK/Ligand)</li> <li>BACE Program (LLY)</li> <li>RG-7129 (Roche)</li> <li>CTS-21166 (CoMentis/Astellas)</li> <li>TAK-070 (Takeda)</li> <li>E2609 (Eisai)</li> </ul>
Other (N=3)			<ul style="list-style-type: none"> <li>NK-002 (Neurokine)*</li> <li>Memryte (Curaxis)</li> <li>Posiphen (QR Pharma)</li> </ul>

Beta Amyloid Targeting (N=39)

NO UNAUTHORIZED USE  
© 2012 LUMLEIAN, LLC



Notes: CAD106 - Payload antibody; Posiphen - APP/Aβ and aSyn translational inhibitor; Memryte - Hypothalamic pituitary gonadal axis changes; NK-002 - Immunomodulator

Sources: Lumleian estimates based on publicly available data from bio-pharmaceutical companies (financial statements, investor presentations, pipeline presentations, analyst day transcripts); 3rd party equity research reports; Bio-Pharma Insight; Clinical Trials.gov; CenterWatch